Phosphoenolpyruvate carboxykinase (PEPCK) 1 and insulinlike growth factor binding protein-1 (IGFBP-1) contribute to glucose homeostasis. PEPCK catalyzes the rate-limiting and committed step in gluconeogenesis (1, 2) . IGFBP-1 binds IGFs in the serum and reduces the amount accessible to cells (3, 4) . The regulation of PEPCK and IGFBP-1 is similar and is primarily a result of regulating the rate of gene transcription (5) (6) (7) (8) , which is induced by glucocorticoids and inhibited by insulin (9 -13) .
Glucocorticoids exert their effects on transcription by binding an intracellular receptor, causing it to translocate to the nucleus and bind to glucocorticoid response elements (GREs) present in the promoters of target genes (14 -16) . However, to effectively mediate induction, the glucocorticoid receptor must interact with accessory factors bound to a variety of sites within complex glucocorticoid response units (GRUs). The GRUs of the PEPCK and IGFBP-1 promoters are very similar, each containing two GREs and multiple accessory factor binding sites (13, 17) . In the PEPCK promoter, the binding sites for accessory factor 1 (AF1) and accessory factor 2 (AF2), which have been shown to bind COUP-TF/HNF4 and forkhead/ winged helix proteins, respectively, lie immediately 5Ј of the GREs, whereas a third accessory factor site (AF3), which binds COUP-TF, is located 3Ј of these sites (18 -21) . All five sites, as well as the cAMP response element (22) , are necessary for maximal glucocorticoid induction of the PEPCK gene (17, 23, 24) . The GRU of the human IGFBP-1 promoter also contains two GREs as well as two accessory factor sites, one of which binds HNF1 and is located downstream of the 3Ј GRE, whereas the other binds forkhead/winged helix proteins and is located immediately upstream of the 3Ј GRE (13, 18, 25) .
O'Brien et al. (26) reported that a sequence present in the AF2 site of the PEPCK GRU conferred insulin inhibition on a linked reporter when inserted into a heterologous thymidine kinase promoter (26) . Mutation of this sequence abolished both insulin inhibition of the thymidine kinase promoter and the binding of nuclear proteins, leading to the conclusion that it was an insulin response sequence (IRS) (26, 27) . Suwanichkul et al. (12, 28) identified two IRSs, IRSA and IRSB, that mediate insulin inhibition of basal IGFBP-1 promoter activity. Goswami et al. (25) found that IRSB overlaps the 3Ј GRE, which was identified by footprinting and functional analysis of mutations in reporter gene assays. Subsequently, it was found that mutation of IRSA, which can bind forkhead/winged helix proteins, impairs induction by glucocorticoids, and it was suggested that these proteins may contribute to regulation of IG-FBP-1 and PEPCK promoter activity by glucocorticoids and insulin (18, 29) . IRSA and IRSB are highly related to the PEPCK IRS, and the IGFBP-1 IRSs also confer insulin inhibi-tion of basal thymidine kinase promoter activity (28) . Highly related IRSs also appear to contribute to insulin inhibition of basal glucagon and glucose-6-phosphatase transcription (30, 31) . Granner and coworkers showed that mutation of the IRS in the PEPCK gene reduces dexamethasone induction, consistent with its activity as a GRU accessory factor binding site (17, 21, 24) , and suggested that insulin signaling to the IRS may disrupt GRU function, leading to inhibition (32, 33) . However, the effect of mutation of the PEPCK IRS on regulation by insulin in the context of the endogenous PEPCK promoter and the roles of forkhead proteins and the IRS in mediating insulin inhibition of glucocorticoid-induced IGFBP-1 transcription have not been reported.
HNF3, a member of the winged helix transcription factor family (34, 35) , was shown to bind the IRSs present in the PEPCK and IGFBP-1 promoters as well as in other promoters (18, 29, 32, 36, 37) , and mutations in the IRSs of the PEPCK or IGFBP-1 genes that reduce HNF3 binding also reduce glucocorticoid-induced transcription (18, 21, 32) . However, transactivation by HNF3 proteins does not appear to be regulated by insulin (38) . FKHR, another member of the winged helix family of transcription factors (34) , binds specifically to IRSs (39) , and IRS-dependent transactivation by FKHR can be suppressed by insulin (38, 40) .
Previous studies showed that insulin activation of PKB and phosphorylation of FKHR are required for inhibition of basal IGFBP-1 transcription (38, 41, 42) . FKHR expression increased IGFBP-1 basal activity in an IRS-dependent manner, an effect that was inhibited by insulin or constitutively active Myr-PKB (38) . Mutation of three putative PKB phosphorylation sites in FKHR to alanine (Thr-24, Ser-256, Ser-319 (T/S/S)) or of Ser-256 alone abolished inhibition of IGFBP-1 transcription by insulin or Myr-PKB, and mutation of Ser-256 to an aspartate residue, a negatively charged amino acid mimicking the effect of phosphorylation, limited induction (38) . Expression of antisense FKHR mRNA reduced IGFBP-1 basal activity to the same extent as insulin or myr-PKB (38) . Thus, insulin-or PKB-mediated phosphorylation of FKHR can inhibit basal IG-FBP-1 transcription (38) . However, these previous studies did not assess the roles of the IRS or FKHR in insulin inhibition of glucocorticoid-induced transcription.
In this paper, we investigated the contribution of FKHR and the IRSs of the PEPCK and IGFBP-1 promoters to basal as well as glucocorticoid-induced transcription and their inhibition by insulin in H4IIe cells, which regulate PEPCK and IGFBP-1 transcription as in vivo (5, 8) . Luciferase reporter gene constructs under control of the PEPCK or IGFBP-1 promoters containing either wild type or mutated IRSs were transfected into H4IIe cells together with expression vectors for either wild type FKHR or a mutant in which three sites that can be phosphorylated by PKB (Thr-24, Ser-256, and Ser-319) are changed to alanines (T/S/S). A DNA binding-defective FKHR (H3-mut (43)) also was tested for its ability to induce basal transcription from PEPCK and IGFBP-1 promoters. Our results show that gene-and activation-specific mechanisms of insulin inhibition exist to regulate PEPCK and IGFBP-1 transcription. FKHR and IRS mediated insulin inhibition of basal, but not glucocorticoid-induced, IGFBP-1 transcription, whereas neither the IRS nor the phosphorylation of putative PKB sites in FKHR appear to be required for insulin regulation of basal or glucocorticoid-induced PEPCK gene transcription.
MATERIALS AND METHODS

H4IIe
Cell Culture and Transfection Analysis-H4IIe cells were grown and transfected as previously described (44, 45) . In brief, the cells were transfected in solution with 10 g of luciferase (firefly) reporter plus 1 g of each expression plasmid plus 1 g of pRL-SV (Renilla luciferase, Promega Corp.) reporter to correct for differences in transfection efficiency. Expression plasmids were omitted in transfections designated None. Half of the cells were seeded into each of two 60-mm dishes, one of which served as a control, whereas the other was later treated with 10 nM insulin. After ϳ6 h, the cells were treated with 20% Me 2 SO for 3 min, washed in PBS, and then incubated in fresh medium with or without 0.5 M dexamethasone and/or 10 nM insulin for ϳ24 h. Cells were harvested with trypsin/EDTA and lysed, and luciferase activities for the firefly and Renilla luciferase reporters were measured with the dual luciferase kit (Promega) using an ALL Monolight 3010 dual injector luminometer. Variations in PEPCK or IGFBP-1 promoter firefly luciferase activity due to variations in transfection efficiency were corrected for by measuring Renilla luciferase activity in the same sample. Values were normalized for transfection efficiency, and the mean was computed for several experiments. All figures represent the results of at least three independent transfection experiments, each of which was normalized to the untreated wild type control, and the data were combined for analysis. The number of experiments for each figure is indicated in the figure legends.
Reporter and Expression Vectors-The PEPCK-Luc luciferase reporter gene constructs are based on the promoterless PGL3-basic vector encoding firefly luciferase, obtained from Promega Corp. and modified to accept PEPCK promoter fragments. Briefly, the polylinker of PGL3 was replaced with the polylinker for pQ-CAT (46) to create pQ-Luc. To construct the PEPCK-Luc reporter plasmid, the HindIII/KpnI fragment of pPL9 (47) (BP1.Luc) and mIRS-IGFBP-1-Luc (IRS.mut, in which both IRSA and IRSB are mutated) plasmids were previously described (41) as was the wild type FKHR and PKB phosphorylation-defective FKHR (T/S/S) (38) . Briefly, the IGFBP-1 promoter containing the SauI/HgaI fragment of the rat IGFBP-1 promoter, which extends 320 base pairs 5Ј from the RNA cap site, was cloned immediately upstream of the luciferase cDNA in pGL2 (Promega) to produce IGFBP-1-Luc. The mIRS-IGFBP-1-Luc reporter was created using unique NheI and BamHI restriction sites to replace IRSA and IRSB with mutated sequences (CAAAACAAACT-TATTTTG to CACCGACGACCAGGCCTG) as previously reported (41) . The wild type FKHR and T/S/S expression vectors contain the complete FKHR cDNA cloned into pAlter.Max (41) , and mutagenesis of the putative PKB phosphorylation sites at Thr-24, Ser-256, and Ser-319 to Ala was described previously by Guo et al. (38) . The DNA bindingdefective FKHR expression vector, containing a mutation of Trp-209 to Gly and His-215 to Pro, was previously described (43) . Mutation of His-215 alone has been shown to disrupt binding of FKHR to the IGFBP-1 IRSs (48). G4-FKHR was constructed by polymerase chain reaction amplification of the region spanning amino acids 593-655 of FKHR with primers encoding 5Ј EcoRI and 3Ј PstI sites and replacement of the EcoRI/PstI fragment of C/EBP in G4-C/EBP (49), thereby fusing amino acids 1-147 of the DNA binding domain of Gal4 to the amino terminus of the FKHR activation domain, with expression driven by the SV40 early promoter. The sequence of the final G4-FKHR product was verified by sequencing. Creation of CRG has been previously described (46) and is a fusion protein containing amino acids 4 -147 of the DNA binding domain of Gal4 to the N terminus of the cAMPresponse element-binding protein (CREB) activation domain (amino acids 1-277). The 5XGT-Luc reporter contains 5 Gal4 binding sites linked to the PEPCK minimal promoter (Ϫ40 to ϩ1) (50).
RESULTS
Effects of FKHR on Basal IGFBP-1 and PEPCK Promoter
Activity-To determine whether FKHR regulates basal expression of the IGFBP-1 and/or PEPCK promoters through their IRS sequences, H4IIe cells were cotransfected with luciferase reporter vectors under the control of promoters with wild type and mutated IRSs and expression vectors for FKHR or FKHR-T/S/S (T/S/S). Expression of FKHR stimulated IGFBP-1-Luc activity, which was effectively inhibited by insulin (Fig. 1A) . In contrast, expression of T/S/S, which cannot be phosphorylated by PKB, also stimulated IGFBP-1-Luc, but was only partially inhibited by insulin. Mutation of IRSA and IRSB in the IG-FBP-1 promoter caused a decrease in basal luciferase activity (Fig. 1B) and also decreased insulin inhibition of basal activity by ϳ50%. Previous reports show that mutation of the IGFBP-1 IRSs abolishes insulin-or PKB-mediated regulation of basal IGFBP-1 activity in HepG2 cells (38, 41) . Expression of either FKHR or T/S/S increased activity of mIRS-IGFBP-1-Luc, although to a lesser extent than for IGFBP-1-Luc, indicating that FKHR interacts with other sites in the IGFBP-1 construct when overexpressed in H4IIe cells. Insulin inhibited mIRS-IGFBP-1 promoter activity stimulated by FKHR by 50% but not that stimulated by T/S/S. This difference in the effectiveness of insulin in suppressing T/S/S-enhanced transcription of the wild type and mIRS-IGFBP-1 promoters may indicate that another IRS-associated factor contributes to induction but not inhibition by insulin in H4IIe cells, or that insulin suppresses transactivation by IRS-associated FKHR in H4IIe cells through a mechanism that does not require phosphorylation of the FKHR sites mutated in T/S/S. PEPCK-Luc expression was inhibited by insulin and stimulated by expression of FKHR or T/S/S (Fig. 2A) . As with IG-FBP-1, expression of FKHR had no effect on insulin inhibition. However, in contrast to the pattern seen with IGFBP-1, expression of T/S/S had little effect on insulin inhibition, suggesting that phosphorylation of putative PKB sites in FKHR is not required for insulin inhibition of basal PEPCK promoter activity. Also, mutation of the PEPCK IRS had no effect on basal activity or its inhibition by insulin (Fig. 2B) , indicating that the IRS is not required for inhibition of basal transcription. The stimulatory activity of FKHR or T/S/S was reduced in mIRS-PEPCK-Luc, but the ability of insulin to inhibit was unaffected. Together, these results indicate that the activity of the IG-FBP-1 and PEPCK IRSs and their association with FKHR are context-dependent. The IGFBP-1 IRSs are crucial for strong FKHR activation, and the putative PKB phosphorylation sites in FKHR contribute to insulin inhibition of basal IGFBP-1 transcription. In contrast, FKHR stimulates PEPCK to a lesser extent than it does IGFBP-1, and neither the IRS nor phosphorylation of putative PKB sites are required for insulin inhibition of basal PEPCK promoter activity.
TABLE I Effects of FKHR and T/S/S on glucocorticoid and insulin regulation of wild type and mIRS IGFBP-1-Luc and PEPCK-Luc
Insulin Inhibition of Glucocorticoid-induced IGFBP-1 and PEPCK Expression Occurs through an IRS-independent Mechanism(s)-
Both the PEPCK and IGFBP-1 IRSs are positioned within glucocorticoid response units, and they have been suggested to disrupt the inducer complex to mediate insulin inhibition of glucocorticoid induction (18, 32, 33) . To test this hypothesis, we examined the effect of expression of FKHR or T/S/S on glucocorticoid-induced activity of wild type and mIRS PEPCK and IGFBP-1 promoters (Table I, Figs. 3 and 4) . Expression of FKHR or T/S/S enhanced both basal and dexamethasone-induced IGFBP-1 (Fig. 3A) and PEPCK (Fig. 4A) transcription. For either IGFBP-1 or PEPCK, mutation of the IRSs decreased dexamethasone induction by 33-67%, consistent with their proposed roles as accessory factors (17, 21, 24) regardless of whether cells were cotransfected with FKHR or not (Table I) . Insulin inhibition of dexamethasone-induced transcription of either promoter was unaffected by mutation of the IRSs or of putative PKB phosphorylation sites in T/S/S. Insulin still inhibited the induction of mIRS-IGFBP-1 by dexamethasone, an effect also seen in HepG2 cells. 2 Expression of FKHR or T/S/S reduced induction of IGFBP-1 by dexamethasone nearly as effectively as mutation of the IRS, but neither FKHR nor T/S/S had any effect upon induction of mIRS-IG-FBP-1 by dexamethasone (Fig. 3B) . Expression of FKHR or T/S/S also reduced the extent of induction of PEPCK-Luc relative to control (Fig. 4B) . These results indicate that endogenous factors may be displaced by overexpressed FKHR, as suggested by the recent studies of Hall et al. (51) and Ghosh et al. (52) . Alternatively, attenuated induction of the mIRS promoter by FKHR may result from squelching through interactions with co-activators, as reported (53, 54) . Together, these data indicate that an IRS-independent mechanism is utilized by insulin to inhibit glucocorticoid-induced IGFBP-1 or PEPCK transcription and that phosphorylation of putative PKB sites in FKHR is not required for this effect.
The Effect of FKHR on Basal IGFBP-1 and PEPCK Transcription Requires DNA Binding-Because the effect of FKHR on transcription was reduced but not eliminated by mutation of the IRS, we tested the activity of a modified form of FKHR in which critical residues within helix 3 of the DNA binding domain are mutated, and DNA binding is disrupted (H3-mut) (43) . As shown in Fig. 5, H3 -mut only slightly stimulated PEPCK-Luc activity and had no effect upon IGFBP-1-Luc activity, indicating that DNA binding is required for stimulation by FKHR. When the carboxyl-terminal activation domain of FKHR (amino acids 593-655) was fused to the Gal4 DNA binding domain and induction was tested using a luciferase reporter under the control of 5 Gal4 binding sites (5XGT-Luc), expression of the Gal4-FKHR fusion protein showed strong induction but no insulin inhibition, suggesting that the presence of the FKHR activation domain is all that is necessary for induction and that other domains within FKHR are required for inhibition of transactivation by insulin.
DISCUSSION
The present study shows that FKHR can interact with IRSs in the IGFBP-1 gene and that insulin can inhibit basal expression by antagonizing this interaction, whereas the PEPCK IRS can bind FKHR, but this is not essential for insulin inhibition of PEPCK promoter activity. Although the PEPCK and IG-FBP-1 IRSs act as accessory factor sites within the GRUs, they are not required for insulin inhibition of glucocorticoid-induced transcription. Insulin inhibition of basal PEPCK expression and glucocorticoid-induced expression of either gene in H4IIe cells is not dependent upon IRSs or phosphorylation of putative PKB sites in FKHR. Thus, despite the fact that the PEPCK and IGFBP-1 genes are regulated very similarly, the data presented here and elsewhere (44, 50, 55) suggest that gene-and activation-specific mechanisms are employed by insulin to inhibit basal and hormone-induced transcription of these genes.
The IRS was first identified by testing candidate sequences for their ability to confer insulin inhibition upon a thymidine kinase promoter when inserted in the Ϫ50 position (26) . An IRS, mutation of which abolished both insulin regulation and specific protein binding, was identified within AF2 of the GRU (26) . In hindsight, it seems that this strategy led to identification of a binding site for FKHR and perhaps other closely related Fox(o) forkhead proteins (61), which, when evaluated in isolation, provide enhancement of basal transcription that can be inhibited by insulin. Subsequently, a much greater appreci-2 S. Cichy and T. Unterman, unpublished data. ation for context-dependent function has emerged from the analysis of complex regulatory units (56 -60) ; in particular, from the elegantly detailed description of the factors cooperating to provide glucocorticoid induction through the GRU of the PEPCK gene provided by Granner and co-workers (17, 19 -21, 23, 24) . Here, we see that the PEPCK IRS in the context of the native GRU contributes to glucocorticoid induction but is not essential for insulin inhibition of transcription. In contrast, the IRSs of the IGFBP-1 gene enhance both basal and glucocorticoid-induced IGFBP-1 transcription and play a crucial role in insulin inhibition of basal transcription, consistent with previous reports (38, 41) .
The location of the PEPCK IRS within AF2 of the GRU suggested that insulin inhibition of glucocorticoid-induced transcription could be mediated by regulation of an IRS-associated factor (32, 33) . The IRSs present in PEPCK, IGFBP-1, and other genes are highly homologous and have been shown to bind FKHR, HNF3, and other related factors (18, 29, 32, 36, 37, 39) of the Fox(o) subgroup (61) of the forkhead/winged helix family. FKHR regulates insulin inhibition of basal IGFBP-1 activity by binding to the IRSs (38, 41) . The extent of induction by dexamethasone of PEPCK and IGFBP-1 promoters bearing variant IRSs is correlated with the ability of the IRS variants to bind forkhead proteins, including FKHR and HNF3 (18, 21, 32) . These findings suggested that the ability of insulin to inhibit transactivation by forkhead proteins may limit glucocorticoid induction of IGFBP-1 and PEPCK promoter activity. Investigation of the role of the IRS in its native context within the GRUs of the PEPCK and IGFBP-1 genes presented here shows that the IRSs are not required for insulin inhibition of glucocorticoid-induced transcription.
In the present study, the major effects of FKHR on either promoter were mediated through the IRS. However, FKHR can act through other sites, and possibly, other factors can act through the IRS. Both FKHR and T/S/S stimulated expression of the mIRS promoters, although less avidly than they stimulated the wild type promoters, suggesting that they can also interact with other sites. The observation that insulin inhibits FKHR-but not T/S/S-induced mIRS-IGFBP-1 transcription also indicates that FKHR can bind sequences other than the IRS and that this interaction can be inhibited by insulin. On the other hand, the observation that insulin only partially inhibited T/S/S-induced transcription of the intact IGFBP-1 promoter suggests either that insulin can suppress transactivation by FKHR through a mechanism that does not require the putative PKB sites in FKHR or that an alternate factor that is regulated by insulin can also bind a site that is disrupted by mutation of the IRS. The latter interpretation is consistent with the observation that mutation of the IRS abolishes all insulin regulation in the presence of T/S/S but only partly in the presence of FKHR. Evidence for such a factor, whose binding is disrupted by mutation of the IRS, was not seen in studies of the IGFBP-1 promoter in HepG2 cells, where all insulin regulation is abolished in mIRS-IGFBP-1 (38) . A precedent for this is that the lack of insulin inhibition of PKA-induced PEPCK promoter activity in HepG2 cells (50) results from differential expression of transcription factors in H4IIe and HepG2 cells that bind a regulatory region involved in insulin inhibition (55) .
The observation that mutation of the IRSs or overexpression of FKHR (wild type or T/S/S) both reduced the extent of dexamethasone induction by ϳ50% also suggests that a factor other than FKHR may bind the IRS to mediate induction by glucocorticoids. A recent study by Hall et al. (51) suggests that endogenous FKHRL1, a homologue of FKHR, may not be involved in the regulation of basal PEPCK or IGFBP-1 transcription except when overexpressed in H4IIe cells. Thus, other factors may contribute to the regulation of promoter activity by both insulin and glucocorticoids through the IRS. In addition, recent evidence suggests that overexpression of FKHR or insulin activation of NFB can sequester CREB binding protein (CBP) and inhibit PEPCK induction (53, 62) . In addition, insulin has direct effects on the glucocorticoid receptor (63) , and insulin can disrupt cooperative interactions with p300/CBP (54) . How such general mechanisms of inhibition can account for very selective induction and inhibition of a variety of hepatic genes by insulin (64, 65) remains to be elucidated.
It is notable that expression of a G4-FKHR fusion protein containing only the carboxyl-terminal activation domain strongly stimulated induction of a G4-dependent, minimal PEPCK promoter and that insulin did not inhibit this effect (Fig. 5C ). Similar results have been obtained in HepG2 cells. 3 In contrast, Tomizawa et al. (40) report that insulin but not PKB could inhibit activation of a G4-FKHR construct containing the final 444 amino acids of the FKHR transactivation domain. Our results indicate that insulin does not inhibit interactions of the minimal transactivation domain in FKHR with other regulators, consistent with the report of Cahill et al. (66) .
Insulin inhibition of transcription appears to be mediated through a variety of gene-and induction-specific mechanisms. We previously demonstrated that the IRS is not required for insulin inhibition of PKA-induced transcription, which is mediated by a cAMP/insulin response unit, distinct from the GRU (50) . In addition, insulin inhibition of basal transcription required only the minimal PEPCK promoter (50) . Here we show that insulin employs distinct mechanisms to inhibit basal and GRU-mediated IGFBP-1 gene expression. Thus, despite overall similarity in the promoter architecture and regulatory patterns of the PEPCK and IGFBP-1 genes, different mechanisms are used by insulin to inhibit basal and inducible expression of the two genes. The utilization of distinct regulatory pathways to mediate regulation of gene transcription in a context-and mechanism-specific manner may be a more general phenomenon, indicating that a variety of transcription factors are regulated, perhaps by distinct insulin-signaling pathways.
